# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02058160` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02058160](<https://clinicaltrials.gov/study/NCT02058160>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02058160

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 736 participants.

## Technical summary

Registry record NCT02058160. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2017-02-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 736 participants (enrolled count; ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Results first posted: 2017-02-10 (ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Chile; Czechia; Denmark; Estonia; Hungary; Lithuania; Mexico; Netherlands; Poland; Romania; Russia; Slovakia; Spain; Sweden; Ukraine (ClinicalTrials.gov record NCT02058160, source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02058160-2017-05-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
- Acronym: LixiLan-L
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin glargine/lixisenatide (HOE901/AVE0010)
- Intervention (Drug): Insulin glargine (HOE901)
- Intervention (Drug): Metformin (Background Drug)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial (`cardio:pubmed-27650977`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial (`cardio:pubmed-28386990`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: acb0e452c9d8168e6b15e5f5707781f85c560c44c633b386dc25d90849f1e087
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
